PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS
PHXA34, A NEW POTENT OCULAR HYPOTENSIVE DRUG - A STUDY ON DOSE-RESPONSE RELATIONSHIP AND ON AQUEOUS-HUMOR DYNAMICS IN HEALTHY-VOLUNTEERS
复制标题
DOI：
10.1001/archopht.1991.01080110100045
复制
发表时间：
1991-11-01
影响因子：
--
通讯作者：
VILLUMSEN, J
中科院分区：
文献类型：
--
作者：
ALM, A;VILLUMSEN, J
前列腺素类似物PhXA34在正常人眼中进行了两项试验；1、3和10 μ g的PhXA34在单次局部给药后6至10小时内，分别使眼压降低约2、3和4 mm Hg。观察到的唯一副作用是10 μ g PhXA34后轻微的结膜充血。在第二项研究中，我们测定了10 μ g PhXA34每天一次，连续7天对眼压、流出设施、水流量、血水屏障通透性、眼部不适和充血的影响。给药后12小时平均眼压低于9毫米汞柱。约三分之一的眼压下降可由流出设施增加来解释。水溶液流动不受影响。口服荧光素1小时后，水溶液荧光增加21%。最初在一半的受试者中观察到轻微的眼部不适和一些充血，但这些副作用的频率和程度在研究期间有所下降。
The prostaglandin analogue PhXA34 was tested in two studies in normal human eyes; 1, 3, and 10-mu-g of PhXA34 reduced the intraocular pressure by about 2, 3, and 4 mm Hg, respectively, 6 to 10 hours after a single topical dose. The only side effect observed was a slight conjunctival hyperemia after 10-mu-g of PhXA34. In a second study we determined the effect of 10-mu-g of PhXA34 once dally for 7 days on intraocular pressure, outflow facility, aqueous flow, blood-aqueous barrier permeability, ocular discomfort, and hyperemia. The mean intraocular pressure was below 9 mm Hg 12 hours post dose. About one third of the intraocular pressure reduction could be explained by increased outflow facility. Aqueous flow was unaffected. Treatment caused a 21% increase in aqueous fluorescence 1 hour after an oral dose of fluorescein. Mild ocular discomfort and some hyperemia were initially observed in half of the subjects, but frequency and magnitude of these side effects declined during the study.